Jin‐Yuan Shih

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

Harbors Met Amplification, Engineering, Pathology +18

Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of <i>TWIST</i> Gene Expression

Hui‐Wen Lo, Sheng-Chieh Hsu, Weiya Xia et al. · Cancer Research · 2007 · 625 citations · Full text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Kang‐Yi Su, Hsuan‐Yu Chen, Ker-Chau Li et al. · Journal of Clinical Oncology · 2012 · 489 citations · Full text

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Jenn‐Yu Wu, Chong‐Jen Yu, Yeun‐Chung Chang et al. · Clinical Cancer Research · 2011 · 461 citations · Full text